SCHEMBL15845818

SCHEMBL15845818

CC(=O)c1ccccc1-c1cc(OCOCC[Si](C)(C)C)c2ncn(COCC[Si](C)(C)C)c(=O)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 2/20 0.38
▸ EGFR P00533 1/20 0.37
▸ IGF1R P08069 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ FLT4 P35916 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ EPHB4 P54760 1/20 0.37
▸ TEK Q02763 1/20 0.37
▸ NPC1 O15118 1/20 0.35
▸ METAP2 P50579 1/20 0.35
▸ BRD4 O60885 3/20 0.34
▸ CREBBP Q92793 1/20 0.34
▸ DGAT1 O75907 3/20 0.33
▸ ALOX5AP P20292 1/20 0.32
▸ FEN1 P39748 1/20 0.32
▸ CTSA P10619 1/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ GRK2 P25098 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17391755 0.93 PTPN11 (0.37) P2RX3EGFRIGF1RSRCFLT4
SCHEMBL15845861 0.91 HTT (0.36) P2RX3EGFRIGF1RSRCFLT4
SCHEMBL15845671 0.90 ALDH1A1 (0.40) EGFRIGF1RSRCFLT4KDR
SCHEMBL15859688 0.85 EGFR (0.39) EGFRIGF1RSRCFLT4KDR
SCHEMBL15845995 0.84 EGFR (0.37) P2RX3EGFRIGF1RSRCFLT4
SCHEMBL15845665 0.83 EGFR (0.36) P2RX3EGFRIGF1RSRCFLT4
SCHEMBL15845809 0.83 EGFR (0.36) P2RX3EGFRIGF1RSRCFLT4
SCHEMBL15846321 0.83 EGFR (0.36) P2RX3EGFRIGF1RSRCFLT4
SCHEMBL15846249 0.83 EGFR (0.36) P2RX3EGFRIGF1RSRCFLT4
SCHEMBL15845720 0.83 EGFR (0.36) P2RX3EGFRIGF1RSRCFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 — — US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 — — EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 — — EP disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 P2RX3 4391/4885EGFR 4189/4885IGF1R 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback